Kiniksa Pharmaceuticals (KNSA) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Kiniksa Pharmaceuticals published the results on October 27, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• All of Kiniksa's revenue in the quarter was ARCALYST net product revenue; license and collaboration revenue was zero in both periods.
• Kiniksa splits ARCALYST profits evenly with Regeneron. Its share of those payments is recorded as collaboration expense, $105.8 million in Q3 2026.

Source: Kiniksa Pharmaceuticals Q3 2026 results, October 27, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

From the earnings release

In its Q3 2026 release, Kiniksa Pharmaceuticals said:

“Kiniksa expects 2026 ARCALYST net product revenue of between $1.045 billion and $1.050 billion, compared to prior guidance of between $980 million and $995 million.”

“Kiniksa expects 2026 R&D expenses of between $160 million and $170 million and 2026 SG&A expenses of between $270 million and $280 million.”

“Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.”

Source: Kiniksa Q3 2026 release, Oct 27, 2026.

This is the company's own guidance as of Oct 27, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the KNSA forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenue in millions and GAAP diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Kiniksa Pharmaceuticals's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 27, 2026

Kiniksa Pharmaceuticals has one commercial product, ARCALYST (rilonacept), a weekly injection that blocks IL-1 alpha and IL-1 beta signaling. Its total revenue of $286.0 million in Q3 2026 was all ARCALYST net product revenue, against $180.9 million a year earlier. Kiniksa said the increase of $105.1 million came mainly from more patients on therapy. (Kiniksa Q3 2026 release, Oct 27, 2026; Kiniksa Form 10-Q, Q3 2026, Oct 27, 2026)

Most of the growth comes from recurrent pericarditis. Kiniksa estimates that about 23% of the 14,000 annual multiple-recurrence patients were on ARCALYST at the end of Q3 2026, that more than 5,450 prescribers have written prescriptions for the condition since launch, and that average total duration of therapy was about 3 years. (Kiniksa Q3 2026 release, Oct 27, 2026)

ARCALYST was discovered by Regeneron, which licensed Kiniksa worldwide rights outside the Middle East and North Africa. Kiniksa splits ARCALYST profits evenly with Regeneron after deducting manufacturing and commercialization costs, and recognized $105.8 million of expense under that arrangement in Q3 2026, against $63.3 million a year earlier. (Kiniksa Form 10-Q, Q3 2026, Oct 27, 2026)

Net revenue is total sales less estimated discounts and allowances, including chargebacks, rebates, returns, copay assistance, and specialty pharmacy and distributor fees. Over the first nine months of 2026 Kiniksa booked $57.1 million of provisions against current-year sales for contractual adjustments, government rebates and returns. (Kiniksa Form 10-Q, Q3 2026, Oct 27, 2026)

Kiniksa Pharmaceuticals earned $0.56 a diluted share in Q3 2026, against $0.23 a year earlier, on net income of $47.3 million. It reports no adjusted EPS. Operating expenses of $231.7 million included collaboration expense of $105.8 million, SG&A of $65.4 million, R&D of $32.8 million and $13.1 million of share-based compensation. (Kiniksa Q3 2026 release, Oct 27, 2026)

Kiniksa recorded an income tax provision of $11.7 million on pre-tax income of $59.1 million, driven mainly by income earned in Switzerland, the UK and the United States and by uncertain tax positions, partly offset by share-based compensation benefits and R&D credits. (Kiniksa Q3 2026 release, Oct 27, 2026; Kiniksa Form 10-Q, Q3 2026, Oct 27, 2026)

Diluted weighted average shares rose to 84,920,060 from 80,035,400 a year earlier. Kiniksa held $568.8 million of cash, cash equivalents and short-term investments at September 30, 2026 and no debt. (Kiniksa Q3 2026 release, Oct 27, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Kiniksa Pharmaceuticals guides full-year ARCALYST net product revenue and expenses in its release. It raised 2026 ARCALYST revenue guidance to $1.045 billion to $1.050 billion, from $980 million to $995 million, and expects 2026 R&D expenses of $160 million to $170 million and SG&A of $270 million to $280 million. (Kiniksa Q3 2026 release, Oct 27, 2026)

Kiniksa expects data from PASTORALE, the Phase 3 trial of KPL-387, a once-monthly injection for recurrent pericarditis, in the second half of 2027, and plans to start a Phase 1 trial of KPL-1161 by the end of 2026. (Kiniksa Q3 2026 release, Oct 27, 2026)

A consensus figure is the average of the models published by the analysts who cover Kiniksa Pharmaceuticals, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Kiniksa Pharmaceuticals's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning KNSA is on is KNSA a buy or a sell?, what analysts expect next is on the KNSA forecast, and what the company does is on the Kiniksa Pharmaceuticals (KNSA) stock page.

Every number on this page can be traced to a document Kiniksa Pharmaceuticals published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.